SCHEMBL24968378

SCHEMBL24968378

COc1ncc(CC(=O)NCCN2CCN(c3ncc(C(F)(F)F)cn3)CC2)cc1C(F)(F)F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.44
PPARG P37231 1/20 0.43
PPARD Q03181 1/20 0.43
PPARA Q07869 1/20 0.43
TIPARP Q7Z3E1 6/20 0.41
CYP2D6 P10635 1/20 0.40
TACR1 P25103 1/20 0.39
TACR3 P29371 1/20 0.39
CHRM2 P08172 1/20 0.39
CHRM1 P11229 1/20 0.39
FAAH O00519 1/20 0.39
BCHE P06276 1/20 0.39
ACHE P22303 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HSP90AA1 P07900 1/20 0.39
MAPT P10636 1/20 0.39
XBP1 P17861 1/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30165051 1.00 POLB (0.44) POLBPPARGPPARDPPARATIPARP
SCHEMBL24967919 0.87 POLB (0.42) POLBPPARGPPARDPPARATIPARP
SCHEMBL24968367 0.81 TIPARP (0.49) POLBPPARGPPARDPPARATIPARP
SCHEMBL24968407 0.80 CHRM2 (0.50) PPARGPPARDPPARATIPARPCHRM2
SCHEMBL30165090 0.80 CHRM2 (0.50) PPARGPPARDPPARATIPARPCHRM2
SCHEMBL27233860 0.79 PPARG (0.45) PPARGPPARDPPARATIPARPALDH1A1
SCHEMBL24967984 0.76 TIPARP (0.61) POLBTIPARPCHRM2CHRM1ALDH1A1
SCHEMBL28982929 0.76 POLB (0.54) POLBPPARGPPARDPPARATIPARP
SCHEMBL24968920 0.75 MEN1 (0.46) PPARGPPARDPPARATIPARPALDH1A1
SCHEMBL24968870 0.75 TIPARP (0.57) POLBPPARGPPARDPPARATIPARP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240351997-A1 NOVEL PARP7 INHIBITOR AND USE THEREOF SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD. (CN) 2024-10-24 US disclosed
EP-4378938-A1 NOVEL PARP7 INHIBITOR AND USE THEREOF Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) 2024-06-05 EP disclosed
CN-117642393-A Novel PARP7 inhibitor and application thereof 上海齐鲁制药研究中心有限公司 2024-03-01 CN disclosed
WO-2023006013-A1 NOVEL PARP7 INHIBITOR AND USE THEREOF 上海齐鲁制药研究中心有限公司 2023-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240351997-A1 NOVEL PARP7 INHIBITOR AND USE THEREOF PARP6, PARP4, PARP3 POLB 197/4885PPARG 3288/4885PPARD 3174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.